Announcements Trials
Browse Landscape

Phase

Phase 1/2 8Phase 1 7Phase 2 5Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Breast 3Dermatologic 2Thoracic 1Other neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma, T-Cell, Cutaneous 1

Interventions

Cyclophosphamide 21fludarabine 12Rituximab 10Vincristine 6Etoposide 6Prednisone 5Doxorubicin 5pembrolizumab 4Radiotherapy 4Methotrexate 4Magnetic Resonance Spectroscopy 4Immunotherapy, Adoptive 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Dexamethasone 4venetoclax 3ibrutinib 3Nivolumab 3Imiquimod 3Ifosfamide 3Exercise 3Biopsy 368Ga-pentixafor 3fludarabine phosphate 2daratumumab 2Transplantation 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2Roflumilast 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × durvalumab × Lymphoid × Clear all
NCT03235869 2018-03-15

Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Withdrawn
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡